☆ 4.8 Letter

T-Cell Transfer Therapy Targeting Mutant KRAS

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Journal

NEW ENGLAND JOURNAL OF MEDICINE

Volume 376, Issue 7, Pages -

Publisher

MASSACHUSETTS MEDICAL SOC

DOI: 10.1056/NEJMc1616637

Keywords

-

Categories

Medicine, General & Internal

Funding

Intramural NIH HHS [Z01 BC010984-01] Funding Source: Medline
NCI NIH HHS [R01 CA197350, R01 CA081488] Funding Source: Medline

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biochemistry & Molecular Biology

Targeting KRAS mutant cancers: from druggable therapy to drug resistance

Chunxiao Zhu, Xiaoqing Guan, Xinuo Zhang, Xin Luan, Zhengbo Song, Xiangdong Cheng, Weidong Zhang, Jiang-Jiang Qin

Summary: KRAS is the most frequently mutated oncogene in various tumor types and has been considered undruggable due to the lack of classic drug binding sites. However, the development of KRAS inhibitors has made KRAS mutations druggable. Despite remarkable clinical responses, resistance to monotherapy of KRAS inhibitors has been observed. Significant progress has been made in understanding the mechanisms of drug resistance to KRAS-mutant inhibitors.

MOLECULAR CANCER (2022)

Add to Collection

Article Nanoscience & Nanotechnology

Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of KRAS-Mutant Non-Small-Cell Lung Cancer

Guolin Zhao, William Ho, Jinxian Chu, Xiaojian Xiong, Bin Hu, Kofi Oti Boakye-Yiadom, Xiaoyang Xu, Xue-Qing Zhang

Summary: A noninvasive aerosol inhalation nanoparticle system has been developed for the treatment of KRAS-mutant non-small-cell lung cancer (NSCLC). The inhalable nanoparticles show effective tumor targeting and enhanced antitumor activity in a mouse model. Compared to systemic delivery, the nebulized nanoparticles demonstrate better biosafety and present a promising gene therapy approach for KRAS-mutant NSCLC and other respiratory diseases.

ACS APPLIED MATERIALS & INTERFACES (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting mutant KRAS

Daniel A. Erlanson, Kevin R. Webster

Summary: The protein KRAS has long been a challenge in cancer drug discovery, but recent years have seen multiple compounds entering clinical trials, targeting the G12C mutant form, showing potential progress in research. Future challenges include finding more inhibitors to cover a wider range of mutations and prevent the development of resistance.

CURRENT OPINION IN CHEMICAL BIOLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

Therapeutics Targeting Mutant KRAS

Kyaw Z. Thein, Amadeo B. Biter, David S. Hong

Summary: Aberrations in the RAS viral oncogene are prevalent in human cancers, particularly in the KRAS isoform where point mutations in codon 12 are present in up to 80% of KRAS-mutant malignancies. Despite the lack of approved KRAS-targeted agents, new impetus in drug development is provided by covalent allosteric inhibitors that target a shallow pocket on the KRAS surface, such as AMG 510 and MRTX849. Combination strategies targeting resistance mechanisms have become crucial in the fight against KRAS-mutant tumors.

ANNUAL REVIEW OF MEDICINE, VOL 72, 2021 (2021)

Add to Collection

Review Chemistry, Medicinal

Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway

Claudia Korzeniecki, Ronny Priefer

Summary: KRAS genes are commonly mutated in cancer, and targeting KRAS mutant cancers has proven difficult due to lack of success with direct inhibitors. Researchers are now focusing on targeting other areas of the MAPK signaling pathway to inhibit KRAS function.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)

Add to Collection

Article Multidisciplinary Sciences

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting

Adham S. Bear, Tatiana Blanchard, Joseph Cesare, Michael J. Ford, Lee P. Richman, Chong Xu, Miren L. Baroja, Sarah McCuaig, Christina Costeas, Khatuna Gabunia, John Scholler, Avery D. Posey, Mark H. O'Hara, Anze Smole, Daniel J. Powell, Benjamin A. Garcia, Robert H. Vonderheide, Gerald P. Linette, Beatriz M. Carreno

Summary: Activating RAS missense mutations are common in human cancers and can be immunologically targeted. By characterizing HLA class I-restricted mKRAS epitopes, the study successfully isolated and transferred mKRAS-specific TCR to CD8(+) T cells, demonstrating cytotoxicity against mKRAS tumor cells from various origins, with lytic activity correlating with peptide-HLA class I complex abundance. Adoptive transfer of mKRAS-TCR engineered CD8(+) T cells led to tumor eradication in a xenograft model, validating mKRAS peptides as epitopes for immune therapies.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Medicine, Research & Experimental

Targeting the undruggable oncogenic KRAS: the dawn of hope

Hande Asimgil, Utku Ertetik, Nedim Can Cevik, Menar Ekizce, Alper Dogruoez, Muazzez Goekalp, Elif Arik-Sever, Rouzanna Istvanffy, Helmut Friess, Guralp Onur Ceyhan, Ihsan Ekin Demir

Summary: KRAS mutations play a crucial role in various cancers, and recent advances in targeting KRAS mutants have shown promising therapeutic potential for patients with lung, pancreatic, and colorectal cancer. In addition, improvements in gene editing, protein engineering, and drug delivery formulations have revolutionized cancer therapy regimens.

JCI INSIGHT (2022)

Add to Collection

Review Cell Biology

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions

Nastaran Karimi, Seyed Javad Moghaddam

Summary: RAS mutations, especially KRAS, are common in human cancers, particularly non-small-cell lung cancer (NSCLC). Despite numerous investigations and clinical trials, therapeutic agents targeting KRAS have encountered limited success due to co-mutations and other restrictive mechanisms.

CELLS (2023)

Add to Collection

Article Immunology

Bispecific antibodies targeting mutant RAS neoantigens

Jacqueline Douglass, Emily Han-Chung Hsiue, Brian J. Mog, Michael S. Hwang, Sarah R. DiNapoli, Alexander H. Pearlman, Michelle S. Miller, Katharine M. Wright, P. Aitana Azurmendi, Qing Wang, Suman Paul, Annika Schaefer, Andrew D. Skora, Marco Dal Molin, Maximilian F. Konig, Qiang Liu, Evangeline Watson, Yana Li, Michael B. Murphy, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Sandra B. Gabelli, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou

Summary: The study isolated specific single-chain variable fragments targeting mutations in the RAS oncogenes. By developing an immunotherapeutic agent capable of killing cancer cells expressing very low levels of RAS-derived antigens, the researchers demonstrated the potential for more specific anticancer therapeutics. The use of CRISPR-mediated alterations provided strong genetic evidence for the specificity of the developed immunotherapeutic agent.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Review Oncology

Targeting KRAS in Non-Small Cell Lung Cancer

Elena Corral de la Fuente, Maria Eugenia Olmedo Garcia, Ana Gomez Rueda, Yolanda Lage, Pilar Garrido

Summary: KRAS is the most frequently altered oncogene in NSCLC, and its mutant tumors have distinct biology and response to treatment, which makes developing effective drugs challenging. The recent discovery of a new pocket in KRAS G12C has led to the development of inhibitors as a new treatment option. However, resistance to targeted KRAS G12C inhibitors is also a concern, and research is ongoing to understand the mechanisms and find suitable drugs. Co-mutations and combination therapy are also areas of interest.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies

Anne-Laure Desage, Camille Leonce, Aurelie Swalduz, Sandra Ortiz-Cuaran

Summary: This article discusses new therapeutic strategies targeting KRAS G12C and promising approaches of combined therapy to overcome acquired resistance, highlighting their importance in non-small cell lung cancer.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Health Care Sciences & Services

Targeting KRAS in Pancreatic Cancer

Darren Cowzer, Mohammed Zameer, Michael Conroy, Walter Kolch, Austin G. Duffy

Summary: This article reviews therapeutic innovations targeting RAS signaling in pancreatic cancer from a clinical perspective. Despite the strong resistance of pancreatic cancer to treatment, new approaches such as inhibiting mutated KRAS, KRAS activators, and effectors show promise in breaking this therapeutic deadlock.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Review Oncology

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Mingying Xie, Xiaoling Xu, Yun Fan

Summary: NSCLC, particularly with KRAS mutations, remains difficult to treat due to limited targeted therapies. New small-molecule KRAS G12C inhibitors show promise in treating KRAS-mutant NSCLC. Additionally, immune efficacy has been observed in patients with KRAS mutations undergoing immunotherapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

T-Cell Immunotherapy against Mutant KRAS for Pancreatic Cancer

Cornelis J. M. Melief

Summary: Pancreatic ductal adenocarcinoma is the deadliest of all common cancers. The study reported remarkable deep and durable tumor shrinkage in a heavily pretreated patient who received an infusion of autologous T cells transduced.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer

Qiming Zhou, Yao Peng, Fenfen Ji, Huarong Chen, Wei Kang, Lam-Shing Chan, Hongyan Gou, Yufeng Lin, Pingmei Huang, Danyu Chen, Qinyao Wei, Hao Su, Cong Liang, Xiang Zhang, Jun Yu, Chi Chun Wong

Summary: SLC25A22 knockout reverts KRAS-mediated immunosuppression in CRC models by suppressing CXCL1 production and impairing MDSC recruitment. Mechanistically, SLC25A22 promotes asparagine-mediated SRC phosphorylation, which drives CXCL1 transcription and MDSC infiltration. Targeting SLC25A22 in combination with anti-PD1 therapy shows promising results in inhibiting MDSC and activating CD8(+) T cells to suppress KRAS-mutant CRC growth.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Gastroenterology & Hepatology

Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects

Xingyi Guo, Weiqiang Lin, Wanqing Wen, Jeroen Huyghe, Stephanie Bien, Qiuyin Cai, Tabitha Harrison, Zhishan Chen, Conghui Qu, Jiandong Bao, Jirong Long, Yuan Yuan, Fangqin Wang, Mengqiu Bai, Goncalo R. Abecasis, Demetrius Albanes, Sonja Berndt, Stephane Bezieau, D. Timothy Bishop, Hermann Brenner, Stephan Buch, Andrea Burnett-Hartman, Peter T. Campbell, Sergi Castellvi-Bel, Andrew T. Chan, Jenny Chang-Claude, Stephen J. Chanock, Sang Hee Cho, David Conti, Albert de la Chapelle, Edith J. M. Feskens, Steven J. Gallinger, Graham G. Giles, Phyllis J. Goodman, Andrea Gsur, Mark Guinter, Marc J. Gunter, Jochen Hampe, Heather Hampel, Richard B. Hayes, Michael Hoffmeister, Ellen Kampman, Hyun Min Kang, Temitope O. Keku, Hyeong Rok Kim, Loic Le Marchand, Soo Chin Lee, Christopher Li, Li Li, Annika Lindblom, Noralane Lindor, Roger L. Milne, Victor Moreno, Neil Murphy, Polly A. Newcomb, Deborah A. Nickerson, Kenneth Offit, Rachel Pearlman, Paul D. P. Pharoah, Elizabeth A. Platz, John D. Potter, Gad Rennert, Lori C. Sakoda, Clemens Schafmayer, Stephanie L. Schmit, Robert E. Schoen, Fredrick R. Schumacher, Martha L. Slattery, Yu-Ru Su, Catherine M. Tangen, Cornelia M. Ulrich, Franzel J. B. van Duijnhoven, Bethany Van Guelpen, Kala Visvanathan, Pavel Vodicka, Ludmila Vodickova, Veronika Vymetalkova, Xiaoliang Wang, Emily White, Alicja Wolk, Michael O. Woods, Graham Casey, Li Hsu, Mark A. Jenkins, Stephen B. Gruber, Ulrike Peters, Wei Zheng

Summary: This study identified multiple genes associated with colorectal cancer risk through a transcriptome-wide association study, including genes in novel loci. Furthermore, previously unreported genes were also discovered in known GWAS-identified loci. Through colocalization analysis, additional putative susceptibility genes were identified, providing new insights into the biological mechanisms underlying CRC development.

GASTROENTEROLOGY (2021)

Add to Collection

Article Genetics & Heredity

Integration of multiomic annotation data to prioritize and characterize inflammation and immune-related risk variants in squamous cell lung cancer

Ryan Sun, Miao Xu, Xihao Li, Sheila Gaynor, Hufeng Zhou, Zilin Li, Yohan Bosse, Stephen Lam, Ming-Sound Tsao, Adonina Tardon, Chu Chen, Jennifer Doherty, Gary Goodman, Stig E. Bojesen, Maria T. Landi, Mattias Johansson, John K. Field, Heike Bickeboeller, H-Erich Wichmann, Angela Risch, Gadi Rennert, Suzanne Arnold, Xifeng Wu, Olle Melander, Hans Brunnstrom, Loic Le Marchand, Geoffrey Liu, Angeline Andrew, Eric Duell, Lambertus A. Kiemeney, Hongbing Shen, Aage Haugen, Mikael Johansson, Kjell Grankvist, Neil Caporaso, Penella Woll, M. Dawn Teare, Ghislaine Scelo, Yun-Chul Hong, Jian-Min Yuan, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Demetrios Albanes, Raymond Mak, David Barbie, Paul Brennan, Rayjean J. Hung, Christopher I. Amos, David C. Christiani, Xihong Lin

Summary: This study prioritizes and characterizes single nucleotide polymorphisms (SNPs) that increase the risk of squamous cell lung cancer by utilizing extensive multiomics data sources and genome-wide functional annotations. The reanalysis of data highlights the impact of SNPs from nuclear factor-kappa B signaling pathway genes and major histocompatibility complex-mediated immune responses on lung cancer. The strategies introduced in this study provide informative and systematic approaches for incorporating genome-wide annotation data in genetic association studies.

GENETIC EPIDEMIOLOGY (2021)

Add to Collection

Article Oncology

Mendelian randomisation study of smoking exposure in relation to breast cancer risk

Hanla A. Park, Sonja Neumeyer, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang, Joe Dennis, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Volker Arndt, Kristan J. Aronson, Annelie Augustinsson, Adinda Baten, Laura E. Beane Freeman, Heiko Becher, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Natalia Bogdanova, Stig E. Bojesen, Hiltrud Brauch, Hermann Brenner, Sara Y. Brucker, Barbara Burwinkel, Daniele Campa, Federico Canzian, Jose E. Castelao, Stephen J. Chanock, Georgia Chenevix-Trench, Christine L. Clarke, Don M. Conroy, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Mary B. Daly, Peter Devilee, Thilo Dork, Isabel Dos-Santos-Silva, Miriam Dwek, Diana M. Eccles, A. Heather Eliassen, Christoph Engel, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Henrik Flyger, Lin Fritschi, Montserrat Garcia-Closas, Jose A. Garcia-Saenz, Mia M. Gaudet, Graham G. Giles, Gord Glendon, Mark S. Goldberg, David E. Goldgar, Anna Gonzalez-Neira, Mervi Grip, Pascal Guenel, Eric Hahnen, Christopher A. Haiman, Niclas Hakansson, Per Hall, Ute Hamann, Sileny Han, Elaine F. Harkness, Steven N. Hart, Wei He, Bernadette A. M. Heemskerk-Gerritsen, John L. Hopper, David J. Hunter, Agnes Jager, Anna Jakubowska, Esther M. John, Audrey Jung, Rudolf Kaaks, Pooja Middha Kapoor, Renske Keeman, Elza Khusnutdinova, Cari M. Kitahara, Linetta B. Koppert, Stella Koutros, Vessela N. Kristensen, Allison W. Kurian, James Lacey, Diether Lambrechts, Loic LeMarchand, Wing-Yee Lo, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Maria ElenaMartinez, Dimitrios Mavroudis, Alfons Meindl, Usha Menon, Roger L. Milne, Taru A. Muranen, Heli Nevanlinna, William G. Newman, Borge G. Nordestgaard, Kenneth Offit, Andrew F. Olshan, Hakan Olsson, Tjoung-Won Park-Simon, Paolo Peterlongo, Julian Peto, Dijana Plaseska-Karanfilska, Nadege Presneau, Paolo Radice, Gad Rennert, Hedy S. Rennert, Atocha Romero, Emmanouil Saloustros, Elinor J. Sawyer, Marjanka K. Schmidt, Rita K. Schmutzler, Minouk J. Schoemaker, Lukas Schwentner, Christopher Scott, Mitul Shah, Xiao-Ou Shu, Jacques Simard, Ann Smeets, Melissa C. Southey, John J. Spinelli, Victoria Stevens, Anthony J. Swerdlow, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Mary Beth Terry, Ian Tomlinson, Melissa A. Troester, Therese Truong, Celine M. Vachon, Elke M. van Veen, Joseph Vijai, Sophia Wang, Camilla Wendt, Robert Winqvist, Alicja Wolk, Argyrios Ziogas, Alison M. Dunning, Paul D. P. Pharoah, Douglas F. Easton, Wei Zheng, Peter Kraft, Jenny Chang-Claude

Summary: Despite a modest association between tobacco smoking and breast cancer risk reported by recent epidemiological studies, the Mendelian randomisation study provides supportive evidence for a potential causal association with breast cancer risk for lifetime smoking exposure but not cigarettes per day among smokers. Sensitivity analyses yielded similar results and showed no strong evidence of pleiotropic effect.

BRITISH JOURNAL OF CANCER (2021)

Add to Collection

Article Biochemical Research Methods

Iam hiQ-a novel pair of accuracy indices for imputed genotypes

Albert Rosenberger, Viola Tozzi, Heike Bickeboeller

Summary: This paper introduces an independent pair of accuracy measures, Iam hiQ, which can be applied to evaluate the output of all imputation software; by applying both measures to a large sample of the International Lung Cancer Consortium (ILCCO), meaningful thresholds for classifying markers of poor accuracy were found.

BMC BIOINFORMATICS (2022)

Add to Collection

Article Pharmacology & Pharmacy

Association of CYP2C19 Polymorphism With Proton Pump Inhibitors Effectiveness and With Fractures in Real-Life: Retrospective Cohort Study

Naomi Gronich, Idit Lavi, Flavio Lejbkowicz, Mila Pinchev, Gad Rennert

Summary: This retrospective cohort study investigates the symptom refractoriness of patients treated with proton pump inhibitors (PPIs) and suggests that polymorphism in the CYP2C19 gene may explain the differences in patient response to PPI treatment. The study found that poor metabolizers of CYP2C19 had a lower risk of abdominal pain and other related symptoms persistence/recurrence compared to normal metabolizers. Additionally, the study found no significant association between poor metabolizer status and the risk of fractures.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk

Yafang Li, Xiangjun Xiao, Jianrong Li, Jinyoung Byun, Chao Cheng, Yohan Bosse, James McKay, Demetrios Albanes, Stephen Lam, Adonina Tardon, Chu Chen, Stig E. Bojesen, Maria T. Landi, Mattias Johansson, Angela Risch, Heike Bickeboeller, H-Erich Wichmann, David C. Christiani, Gad Rennert, Susanne Arnold, Gary Goodman, John K. Field, Michael P. A. Davies, Sanjay S. Shete, Loic Le Marchand, Olle Melander, Hans Brunnstrom, Geoffrey Liu, Rayjean J. Hung, Angeline S. Andrew, Lambertus A. Kiemeney, Hongbing Shen, Ryan Sun, Shan Zienolddiny, Kjell Grankvist, Mikael Johansson, Neil Caporaso, Dawn M. Teare, Yun-Chul Hong, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Ann G. Schwartz, Ivan Gorlov, Kristen Purrington, Ping Yang, Yanhong Liu, Younghun Han, Joan E. Bailey-Wilson, Susan M. Pinney, Diptasri Mandal, James C. Willey, Colette Gaba, Paul Brennan, Christopher Amos

Summary: Sex differences in lung cancer risk have not been well studied despite the success in lung cancer association studies. By analyzing genotypes from a lung cancer cohort, we identified three low-frequency variants with differential risk effects in men and women. Further analysis suggested that one of the variants affects lung cancer risk through regulation of CXADR gene expression.

HUMAN MOLECULAR GENETICS (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Selective serotonin reuptake inhibitors associated with increased mortality risk in breast cancer patients in Northern Israel

Avital Fischer, Hedy S. Rennert, Gad Rennert

Summary: The study found that the use of SSRIs before and after breast cancer diagnosis is associated with increased mortality in breast cancer patients. Research is needed to further understand the mechanisms behind this association.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2022)

Add to Collection

Article Biology

Rare germline copy number variants (CNVs) and breast cancer risk

Joe Dennis, Jonathan P. Tyrer, Logan C. Walker, Kyriaki Michailidou, Leila Dorling, Manjeet K. Bolla, Qin Wang, Thomas U. Ahearn, Irene L. Andrulis, Hoda Anton-Culver, Natalia N. Antonenkova, Volker Arndt, Kristan J. Aronson, Laura E. Beane Freeman, Matthias W. Beckmann, Sabine Behrens, Javier Benitez, Marina Bermisheva, Natalia Bogdanova, Stig E. Bojesen, Hermann Brenner, Jose E. Castelao, Jenny Chang-Claude, Georgia Chenevix-Trench, Christine L. Clarke, J. Margriet Collee, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Peter Devilee, Thilo Dork, Laure Dossus, A. Heather Eliassen, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Jonine Figueroa, Olivia Fletcher, Henrik Flyger, Lin Fritschi, Marike Gabrielson, Manuela Gago-Dominguez, Montserrat Garcia-Closas, Graham G. Giles, Anna Gonzalez-Neira, Pascal Guenel, Eric Hahnen, Christopher A. Haiman, Per Hall, Antoinette Hollestelle, Reiner Hoppe, John L. Hopper, Anthony Howell, Agnes Jager, Anna Jakubowska, Esther M. John, Nichola Johnson, Michael E. Jones, Audrey Jung, Rudolf Kaaks, Renske Keeman, Elza Khusnutdinova, Cari M. Kitahara, Yon-Dschun Ko, Veli-Matti Kosma, Stella Koutros, Peter Kraft, Vessela N. Kristensen, Katerina Kubelka-Sabit, Allison W. Kurian, James Lacey, Diether Lambrechts, Nicole L. Larson, Martha Linet, Alicja Ogrodniczak, Arto Mannermaa, Siranoush Manoukian, Sara Margolin, Dimitrios Mavroudis, Roger L. Milne, Taru A. Muranen, Rachel A. Murphy, Heli Nevanlinna, Janet E. Olson, Hakan Olsson, Tjoung-Won Park-Simon, Charles M. Perou, Paolo Peterlongo, Dijana Plaseska-Karanfilska, Katri Pylkas, Gad Rennert, Emmanouil Saloustros, Dale P. Sandler, Elinor J. Sawyer, Marjanka K. Schmidt, Rita K. Schmutzler, Rana Shibli, Ann Smeets, Penny Soucy, Melissa C. Southey, Anthony J. Swerdlow, Rulla M. Tamimi, Jack A. Taylor, Lauren R. Teras, Mary Beth Terry, Ian Tomlinson, Melissa A. Troester, Therese Truong, Celine M. Vachon, Camilla Wendt, Robert Winqvist, Alicja Wolk, Xiaohong R. Yang, Wei Zheng, Argyrios Ziogas, Jacques Simard, Alison M. Dunning, Paul D. P. Pharoah, Douglas F. Easton

Summary: This study investigates the potential associations between rare germline copy number variants (CNVs) and breast cancer using a genome-wide analysis in a large breast cancer case-control dataset. The study identifies associations between exonic deletions in established breast cancer susceptibility genes and suggests potential associations for non-coding CNVs in both known and novel loci with large effects sizes.

COMMUNICATIONS BIOLOGY (2022)

Add to Collection

Article Oncology

Beyond GWAS of Colorectal Cancer: Evidence of Interaction with Alcohol Consumption and Putative Causal Variant for the 10q24.2 Region

Kristina M. Jordahl, Anna Shcherbina, Andre E. Kim, Yu-Ru Su, Yi Lin, Jun Wang, Conghui Qu, Demetrius Albanes, Volker Arndt, James W. Baurley, Sonja I. Berndt, Stephanie A. Bien, D. Timothy Bishop, Emmanouil Bouras, Hermann Brenner, Daniel D. Buchanan, Arif Budiarto, Peter T. Campbell, Robert Carreras-Torres, Graham Casey, Tjeng Wawan Cenggoro, Andrew Chan, David Conti, Christopher H. Dampier, Matthew A. Devall, Virginia Diez-Obrero, Niki Dimou, David A. Drew, Jane C. Figueiredo, Steven Gallinger, Graham G. Giles, Stephen B. Gruber, Andrea Gsur, Marc J. Gunter, Heather Hampel, Sophia Harlid, Tabitha A. Harrison, Akihisa Hidaka, Michael Hoffmeister, Jeroen R. Huyghe, Mark A. Jenkins, Amit Joshi, Temitope Keku, Susanna C. Larsson, Loic Le Marchand, Juan Pablo Lewinger, Li Li, Bharuno Mahesworo, Victor Moreno, John L. Morrison, Neil Murphy, Hongmei Nan, Rami Nassir, Polly A. Newcomb, Mireia Obon-Santacana, Shuji Ogino, Jennifer Ose, Rish K. Pai, Julie R. Palmer, Nikos Papadimitriou, Bens Pardamean, Anita R. Peoples, Paul D. P. Pharoah, Elizabeth A. Platz, John Potter, Ross L. Prentice, Gad Rennert, Edward Ruiz-Narvaez, Lori C. Sakoda, Peter C. Scacheri, Stephanie L. Schmit, Robert E. Schoer, Martha L. Slattery, Mariana C. Stern, Catherine M. Tangen, Stephen N. Thibodeau, Duncan C. Thomas, Yu Tian, Konstantinos K. Tsilidis, Cornelia M. Ulrich, Franzel J. B. van Duijnhoven, Bethany Van Guelpen, Kala Visvanathan, Pavel Vodicka, Emily White, Alicja Wolk, Michael O. Woods, Anna H. Wu, Natalia Zemlianskaia, Jenny Chang-Claude, W. James Gauderman, Li Hsu, Anshul Kundaje, Ulrike Peters

Summary: This study reveals that the association between colorectal cancer and the 10q24.2/COX15 gene region is strongest in nondrinkers. The rs1318920 variant is identified as the putative causal regulatory variant for this region, suggesting a possible multifaceted functional effect.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Add to Collection

Article Oncology

A Large-Scale Genome-Wide Gene-Gene Interaction Study of Lung Cancer Susceptibility in Europeans With a Trans-Ethnic Validation in Asians

Ruyang Zhang, Sipeng Shen, Yongyue Wei, Ying Zhu, Yi Li, Jiajin Chen, Jinxing Guan, Zoucheng Pan, Yuzhuo Wang, Meng Zhu, Junxing Xie, Xiangjun Xiao, Dakai Zhu, Yafang Li, Demetrios Albanes, Maria Teresa Landi, Neil E. Caporaso, Stephen Lam, Adonina Tardon, Chu Chen, Stig E. Bojesen, Mattias Johansson, Angela Risch, Heike Bickeboeller, H-Erich Wichmann, Gadi Rennert, Susanne Arnold, Paul Brennan, James D. McKay, John K. Field, Sanjay S. Shete, Loic Le Marchand, Geoffrey Liu, Angeline S. Andrew, Lambertus A. Kiemeney, Shan Zienolddiny-Narui, Annelie Behndig, Mikael Johansson, Angela Cox, Philip Lazarus, Matthew B. Schabath, Melinda C. Aldrich, Juncheng Dai, Hongxia Ma, Yang Zhao, Zhibin Hu, Rayjean J. Hung, Christopher Amos, Hongbing Shen, Feng Chen, David C. Christiani

Summary: In this study, important gene-gene interactions that influence the risk of non-small cell lung cancer (NSCLC) were identified and enriched in the 5p15.33 and 6p21.32 regions. These findings have the potential to improve lung cancer screening models.

JOURNAL OF THORACIC ONCOLOGY (2022)

Add to Collection

Article Oncology

Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application

A. Echle, N. Ghaffari Laleh, P. Quirke, H. Grabsch, H. S. Muti, O. L. Saldanha, S. F. Brockmoeller, P. A. van den Brandt, G. G. A. Hutchins, S. D. Richman, K. Horisberger, C. Galata, M. P. Ebert, M. Eckardt, M. Boutros, D. Horst, C. Reissfelder, E. Alwers, T. J. Brinker, R. Langer, J. C. A. Jenniskens, K. Offermans, W. Mueller, R. Gray, S. B. Gruber, J. K. Greenson, G. Rennert, J. D. Bonner, D. Schmolze, J. Chang-Claude, H. Brenner, C. Trautwein, P. Boor, D. Jaeger, N. T. Gaisa, M. Hoffmeister, N. P. West, J. N. Kather

Summary: This study developed an AI-based system to identify microsatellite instability/mismatch repair deficiency in colorectal cancer, achieving high accuracy. The system can be used to rule out MSI/dMMR, reducing the cost and time for molecular profiling.

ESMO OPEN (2022)

Add to Collection

Article Oncology

Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk

Yu Tian, Andre E. Kim, Stephanie A. Bien, Yi Lin, Conghui Qu, Tabitha A. Harrison, Robert Carreras-Torres, Virginia Diez-Obrero, Niki Dimou, David A. Drew, Akihisa Hidaka, Jeroen R. Huyghe, Kristina M. Jordahl, John Morrison, Neil Murphy, Mireia Obon-Santacana, Cornelia M. Ulrich, Jennifer Ose, Anita R. Peoples, Edward A. Ruiz-Narvaez, Anna Shcherbina, Mariana C. Stern, Yu-Ru Su, Franzel J. B. van Duijnhoven, Volker Arndt, James W. Baurley, Sonja Berndt, D. Timothy Bishop, Hermann Brenner, Daniel D. Buchanan, Andrew T. Chan, Jane C. Figueiredo, Steven Gallinger, Stephen B. Gruber, Sophia Harlid, Michael Hoffmeister, Mark A. Jenkins, Amit D. Joshi, Temitope O. Keku, Susanna C. Larsson, Loic Le Marchand, Li Li, Graham G. Giles, Roger L. Milne, Hongmei Nan, Rami Nassir, Shuji Ogino, Arif Budiarto, Elizabeth A. Platz, John D. Potter, Ross L. Prentice, Gad Rennert, Lori C. Sakoda, Robert E. Schoen, Martha L. Slattery, Stephen N. Thibodeau, Bethany Van Guelpen, Kala Visvanathan, Emily White, Alicja Wolk, Michael O. Woods, Anna H. Wu, Peter T. Campbell, Graham Casey, David Conti, Marc J. Gunter, Anshul Kundaje, Juan Pablo Lewinger, Victor Moreno, Polly A. Newcomb, Bens Pardamean, Duncan C. Thomas, Konstantinos K. Tsilidis, Ulrike Peters, W. James Gauderman, Li Hsu, Jenny Chang-Claude

Summary: This study investigated the gene-environment interaction between menopausal hormone therapy (MHT) and colorectal cancer (CRC) risk. The results showed associations between MHT use and reduced CRC risk, as well as identified specific genetic variants that modify this association, providing new insights into CRC carcinogenesis and potential mechanisms involved.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Add to Collection

Article Oncology

Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study

Alexi N. Archambault, Jihyoun Jeon, Yi Lin, Minta Thomas, Tabitha A. Harrison, D. Timothy Bishop, Hermann Brenner, Graham Casey, Andrew T. Chan, Jenny Chang-Claude, Jane C. Figueiredo, Steven Gallinger, Stephen B. Gruber, Marc J. Gunter, Feng Guo, Michael Hoffmeister, Mark A. Jenkins, Temitope O. Keku, Loic Le Marchand, Li Li, Victor Moreno, Polly A. Newcomb, Rish Pai, Patrick S. Parfrey, Gad Rennert, Lori C. Sakoda, Jeffrey K. Lee, Martha L. Slattery, Mingyang Song, Aung Ko Win, Michael O. Woods, Neil Murphy, Peter T. Campbell, Yu-Ru Su, Iris Lansdorp-Vogelaar, Elisabeth F. P. Peterse, Yin Cao, Anne Zeleniuch-Jacquotte, Peter S. Liang, Mengmeng Du, Douglas A. Corley, Li Hsu, Ulrike Peters, Richard B. Hayes

Summary: This study developed risk prediction models for early-onset colorectal cancer (CRC) that incorporate an environmental risk score (ERS) and a polygenic risk score (PRS). The study found that increasing values of ERS and PRS were associated with increasing relative risks for early-onset CRC. Personal risk scores have the potential to identify individuals at differential relative and absolute risk for early-onset CRC, and may improve screening and outcomes.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Add to Collection

Article Medicine, Research & Experimental

Gene-gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer

Albert Rosenberger, Nils Muttray, Rayjean J. Hung, David C. Christiani, Neil E. Caporaso, Geoffrey Liu, Stig E. Bojesen, Loic Le Marchand, Demetrios Albanes, Melinda C. Aldrich, Adonina Tardon, Guillermo Fernandez-Tardon, Gad Rennert, John K. Field, Michael P. A. Davies, Triantafillos Liloglou, Lambertus A. Kiemeney, Philip Lazarus, Bernadette Wendel, Aage Haugen, Shanbeh Zienolddiny, Stephen Lam, Matthew B. Schabath, Angeline S. Andrew, Eric J. Duell, Susanne M. Arnold, Gary E. Goodman, Chu Chen, Jennifer A. Doherty, Fiona Taylor, Angela Cox, Penella J. Woll, Angela Risch, Thomas R. Muley, Mikael Johansson, Paul Brennan, Maria Teresa Landi, Sanjay S. Shete, Christopher Amos, Heike Bickeboeller

Summary: This study assessed the association and predictive ability of AhR/Wnt genes with lung cancer in individuals of European descent. The results showed no genome-wide significant association with overall lung cancer, but significant associations were observed in subgroups of ever smokers and never smokers. Although the predictability is poor, AhR/Wnt variants are overrepresented in optimized prediction scores for lung cancer.

EUROPEAN JOURNAL OF MEDICAL RESEARCH (2022)

Add to Collection

Article Oncology

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Thomas U. Ahearn, Haoyu Zhang, Kyriaki Michailidou, Roger L. Milne, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Michael Lush, Qin Wang, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Annelie Augustinsson, Adinda Baten, Heiko Becher, Sabine Behrens, Javier Benitez, Marina Bermisheva, Carl Blomqvist, Stig E. Bojesen, Bernardo Bonanni, Anne-Lise Borresen-Dale, Hiltrud Brauch, Hermann Brenner, Angela Brooks-Wilson, Thomas Bruening, Barbara Burwinkel, Saundra S. Buys, Federico Canzian, Jose E. Castelao, Jenny Chang-Claude, Stephen J. Chanock, Georgia Chenevix-Trench, Christine L. Clarke, J. Margriet Collee, Angela Cox, Simon S. Cross, Kamila Czene, Mary B. Daly, Peter Devilee, Thilo Dork, Miriam Dwek, Diana M. Eccles, D. Gareth Evans, Peter A. Fasching, Jonine Figueroa, Giuseppe Floris, Manuela Gago-Dominguez, Susan M. Gapstur, Jose A. Garcia-Saenz, Mia M. Gaudet, Graham G. Giles, Mark S. Goldberg, Anna Gonzalez-Neira, Grethe I. Grenaker Alnaes, Mervi Grip, Pascal Guenel, Christopher A. Haiman, Per Hall, Ute Hamann, Elaine F. Harkness, Bernadette A. M. Heemskerk-Gerritsen, Bernd Holleczek, Antoinette Hollestelle, Maartje J. Hooning, Robert N. Hoover, John L. Hopper, Anthony Howell, Milena Jakimovska, Anna Jakubowska, Esther M. John, Michael E. Jones, Audrey Jung, Rudolf Kaaks, Saila Kauppila, Renske Keeman, Elza Khusnutdinova, Cari M. Kitahara, Yon-Dschun Ko, Stella Koutros, Vessela N. Kristensen, Ute Kruger, Katerina Kubelka-Sabit, Allison W. Kurian, Kyriacos Kyriacou, Diether Lambrechts, Derrick G. Lee, Annika Lindblom, Martha Linet, Jolanta Lissowska, Ana Llaneza, Wing-Yee Lo, Robert J. MacInnis, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Maria Elena Martinez, Catriona McLean, Alfons Meindl, Usha Menon, Heli Nevanlinna, William G. Newman, Jesse Nodora, Kenneth Offit, Hakan Olsson, Nick Orr, Tjoung-Won Park-Simon, Alpa Patel, Julian Peto, Guillermo Pita, Dijana Plaseska-Karanfilska, Ross Prentice, Kevin Punie, Katri Pylkas, Paolo Radice, Gad Rennert, Atocha Romero, Thomas Ruediger, Emmanouil Saloustros, Sarah Sampson, Dale P. Sandler, Elinor J. Sawyer, Rita K. Schmutzler, Minouk J. Schoemaker, Ben Schottker, Mark E. Sherman, Xiao-Ou Shu, Snezhana Smichkoska, Melissa C. Southey, John J. Spinelli, Anthony J. Swerdlow, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Lauren R. Teras, Mary Beth Terry, Diana Torres, Melissa A. Troester, Celine M. Vachon, Carolien H. M. van Deurzen, Elke M. van Veen, Philippe Wagner, Clarice R. Weinberg, Camilla Wendt, Jelle Wesseling, Robert Winqvist, Alicja Wolk, Xiaohong R. Yang, Wei Zheng, Fergus J. Couch, Jacques Simard, Peter Kraft, Douglas F. Easton, Paul D. P. Pharoah, Marjanka K. Schmidt, Montserrat Garcia-Closas, Nilanjan Chatterjee

Summary: This study identifies breast cancer susceptibility variants that are associated with tumor features and intrinsic molecular subtypes, providing insights for subtype-specific risk prediction.

BREAST CANCER RESEARCH (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.